Table 3.

Subgroup analysis of remission at post-treatment for all studies

Variable	No of studies	Odds ratio (95% CI)	Chi2	I2	P value	Statistical power
Type of other active treatment options
Combined therapy vs pharmacotherapy	5	1.36 (0.83 to 2.23)	4.80	17%	0.31	62%
Combined therapy vs psychotherapy	3	1.18 (0.33 to 4.23)	6.18	68%	0.05	36%
Combined therapy vs Pill-PBO combined psychotherapy	5	1.36 (0.67 to 2.79)	6.17	35%	0.19	27%
Type of medication combined therapy
Fluoxetine combined therapy	4	1.90 (1.10 to 3.29)	5.32	44%	0.15	99%
Other SSRIs combined therapy	6	0.83 (0.51 to 1.35)	2.58	0%	0.77	6%
Non-SSRIs combined therapy	3	2.46 (1.06 to 5.72)	0.54	0%	0.77	28%
Type of psychotherapy combined therapy
CBT combined therapy	11	1.31 (0.87 to 1.98)	16.23	38%	0.09	92%
Non-CBT combined therapy	2	2.79 (0.76 to 10.22)	0.48	0%	0.49	36%
Severity of baseline symptom
Mild severity	3	1.45 (0.28 to 7.46)	3.63	45%	0.16	14%
Moderate to server severity	10	1.39 (0.93 to 2.06)	13.94	35%	0.12	94%
Treatment duration
Treatment ≤ 8 weeks	4	1.31 (0.65 to 2.64)	5.14	42%	0.16	23%
Treatment > 8 weeks	9	1.42 (0.87 to 2.33)	12.45	36%	0.13	88%
Country
USA	8	1.90 (1.33 to 2.73)	8.07	13%	0.33	100%
Non-USA	5	0.62 (0.32 to 1.17)	0.18	0%	1.00	40%
Risk of bias
Low risk	3	1.39 (0.40 to 4.86)	3.59	44%	0.17	5%
Some concerns	6	0.92 (0.47 to 1.79)	6.89	27%	0.23	12%
High risk	4	1.89 (1.19 to 3.01)	4.32	31%	0.23	98%

Significant results are bolded and underscored

CI confidence interval, P level of significance of heterogeneity, I² measure of heterogeneity, Pill-PBO Pill placebo, SSRIs Selective serotonin reuptake inhibitors, CBT Cognitive behavioural therapy, USA United States of America